|
|
| HITRIplus Newsletter |
| November 2024 |
|
|
|
|
Dear Readers,
Welcome to the November 2024 edition of the HITRIplus newsletter! This month, we’re pleased to share highlights from the Hadron Therapy Symposium in Thessaloniki, recent insights from London Global Cancer Week, and groundbreaking research on Minibeam Radiation Therapy (MBRT). We also spotlight inspiring presentations by Prof. Manjit Dosanjh on expanding cancer care in low-resource settings and Dr. Sanja Damjanovic on SEEIIST’s mission in South-East Europe. Plus, don’t miss our preview of FRPT 2024 in Rome, exploring the future of FLASH and particle therapies.
Thank you for joining us as we drive forward innovation and access in particle therapy. Enjoy the read!
Best regards,
The HITRIplus Communications Team |
|
|
|
|
| Hadron Therapy Symposium: Advancing Cancer Treatment through Collaboration and Innovation |
| Discover insights from the recent Hadron Therapy Symposium in Thessaloniki, where over 400 experts, researchers, and clinicians from 53 countries came together to discuss the latest advancements and challenges in hadron therapy. With sessions on cutting-edge technologies, treatment planning, and new clinical applications, this symposium was a powerful platform for global collaboration. Don’t miss this inside look at a transformative event for particle therapy! |
|
|
|
|
|
|
|
|
| FRPT 2024 in Rome: Exploring the Future of Cancer Treatment |
| Join the FRPT 2024 Conference in Rome from December 4-6, 2024, to explore the latest in FLASH radiotherapy and ultra-high dose rate (UHDR) treatments. This event will bring together leading scientists for rigorous discussions and interactive sessions on the potential of FLASH therapy to redefine cancer treatment. Dive into the forefront of cancer therapy innovation with us in Rome! |
|
|
|
|
|
|
|
|
 |
| Exploring Minibeam Radiation Therapy (MBRT) at the 18th HITRIplus Seminar |
Our latest seminar delved into the promising field of Minibeam Radiation Therapy (MBRT) with presentations by Prof. Yolanda Prezado from Institut Curie and Dr. Michael Grams from the Mayo Clinic. Both experts shared groundbreaking insights into MBRT’s unique biological effects, such as enhanced immune responses and its potential for treating challenging cases. Prof. Prezado discussed the high concentration of T cells in MBRT-treated tumors, while Dr. Grams highlighted the logistical and technical advances needed for MBRT's first clinical applications. As they emphasized, this evolving therapy could offer new hope for radioresistant cancers and re-irradiation cases.
Key Takeaways:
- MBRT and Immunology: Prof. Prezado revealed how MBRT boosts T cell concentration in tumors, suggesting a unique pathway for immune activation.
- Clinical Applications: Dr. Grams outlined the challenges and innovations in translating MBRT from research to patient treatment, especially for complex cases where conventional therapies may fall short.
Discover how MBRT could reshape the future of radiotherapy in challenging cancer treatments by exploring their full insights in this issue. |
|
|
|
|
 |
| Physics for Development: SEEIIST’s Mission for Cancer Therapy in South-East Europe |
| Dr. Sanja Damjanovic represented SEEIIST at the Physics for Development Colloquium, where she highlighted the potential of Hadron Therapy for South-East Europe. Honoring Professor Dr. Hans Joachim Specht’s legacy, this presentation reinforced SEEIIST’s commitment to bridging gaps in advanced cancer treatment. Watch the video to learn more about SEEIIST’s mission to bring cutting-edge healthcare to underserved regions. |
|
|
|
|
 |
| Physics Matters: Transforming Cancer Treatment in Low-Resource Settings |
| During the Physics Matters Colloquium, Prof. Manjit Dosanjh presented on the pressing need for equitable cancer treatment in low-resource settings, introducing Project STELLA as a model for expanding radiotherapy access. This impactful talk showcased HITRIplus’s global networking efforts and the power of science diplomacy to bridge healthcare disparities. Learn more about HITRIplus’s mission to connect stakeholders and improve cancer care accessibility worldwide. |
|
|
|
|
 |
| HITRIplus Networking Pillar at London Global Cancer Week |
| Our Networking Pillar recently participated in London Global Cancer Week, where Prof. Manjit Dosanjh presented on the global role of AI in expanding access to radiotherapy. With insights from the ART study, this session underscored HITRIplus’s mission to address disparities in cancer care access. Explore how HITRIplus is advancing global equity in radiotherapy access through collaborative efforts. |
|
|
|
|
|
You receive this email as you subscribed to HITRIplus general newsletter in order to receive, via email, information and news about the activities of the HITRIplus Project, including invitations to participate in events or surveys and fundraising campaigns.
You can read more information about this data processing here: https://www.hitriplus.eu/privacy_policy/7410/
You can always opt-out selecting the unsubscribe option above.
petya.n.georgieva@gmail.com
©2024 HITRIplus |
|
|
|
